Literature DB >> 1545125

Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

M Honda1, S Yamamoto, M Cheng, K Yasukawa, H Suzuki, T Saito, Y Osugi, T Tokunaga, T Kishimoto.   

Abstract

By using a fluorescence sandwich ELISA for the quantification of soluble human IL-6R, normal human PBMC were found to be induced to release IL-6R into culture supernatant by stimulation with PHA. Furthermore, certain promonocyte cell lines and human T-cell leukemia virus I (HTLV-I)-positive cell lines produced sIL-6R into culture supernatants constitutively. However, this was not found with HTLV-I negative T cell lines and Burkitt's B cell line. In addition, generation of supernatant IL-6R of the promonocyte cell line was significantly increased 27-fold after PMA treatment and sevenfold after infection with HIV. The released IL-6R molecules were characterized as an apparent m.w. of 50 to 55 kDa by both size-exclusion HPLC and immunoprecipitation of the soluble protein with IL-6R-specific mAb followed by SDS-PAGE analysis. Furthermore, increased levels of serum IL-6R were detected in blood donors seropositive for HIV. Moreover, the released IL-6R could bind efficiently to purified rIL-6 on solid phase and suppressed the proliferative responses of PBMC. These results suggest that the release of soluble IL-6R might be linked to regulatory functions of immune responses induced by IL-6 stimulation during normal and human retrovirus-infected cell growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  71 in total

1.  Definition and characterization of an inhibitor for interleukin-31.

Authors:  Emilie Venereau; Caroline Diveu; Linda Grimaud; Elisa Ravon; Josy Froger; Laurence Preisser; Yannic Danger; Mike Maillasson; Laure Garrigue-Antar; Yannick Jacques; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

2.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

3.  Low follicular fluid IL-6 levels in IVF patients are associated with increased likelihood of clinical pregnancy.

Authors:  Tugba Altun; Sangita Jindal; Keri Greenseid; Jun Shu; Lubna Pal
Journal:  J Assist Reprod Genet       Date:  2010-11-03       Impact factor: 3.412

4.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 5.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 6.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

7.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha.

Authors:  V Modur; Y Li; G A Zimmerman; S M Prescott; T M McIntyre
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 8.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.